Oneness Biotech

4743.TWO

1.62 USD

-0.02

-1.22%

Overview

Last close

1.62 usd

Market cap

775.30M usd

52 week high

3.91 usd

52 week low

1.56 usd

Target price

9.77 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

189.3353

Price/Book Value

2.3941

Enterprise Value

611.56M usd

EV/Revenue

149.3345

EV/EBITDA

-91.0869

Key financials

Revenue TTM

4.10M usd

Gross Profit TTM

1.26M usd

EBITDA TTM

-16.38M usd

Earnings per Share

-0.07 usd

Dividend

N/A usd

Total assets

373.81M usd

Net debt

N/A usd

About

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, a wound care medical device. The company develops ON101, has completed clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II a clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has received US FDA Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, for the treatment of COVID that is in Phase II clinical trials; and SNS851 for weight loss and metabolism diseases. In addition, the company engages in the agricultural product cultivation and organic food sales business; and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.